List of Excipients in Branded Drug RAZADYNE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	RAZADYNE	galantamine hydrobromide	21695-184	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	RAZADYNE	galantamine hydrobromide	21695-184	CROSPOVIDONE
Rebel Distributors Corp	RAZADYNE	galantamine hydrobromide	21695-184	FERRIC OXIDE RED
Rebel Distributors Corp	RAZADYNE	galantamine hydrobromide	21695-184	HYPROMELLOSES

Razadyne Excipient Strategy and Commercial Opportunities for Galantamine Products

Last updated: September 24, 2026

Razadyne, the branded galantamine product for mild-to-moderate Alzheimer’s disease, has limited remaining brand exclusivity and substantial generic competition. Its commercial opportunity is therefore concentrated in differentiated formulations, excipient optimization, patient adherence, supply reliability, and lifecycle products rather than conventional molecule-level exclusivity.

Razadyne is marketed in three oral dosage forms:

Product	Active ingredient	Strengths	Release profile
Razadyne tablets	Galantamine hydrobromide	4 mg, 8 mg, 12 mg	Immediate release
Razadyne oral solution	Galantamine hydrobromide	4 mg/mL	Immediate release
Razadyne ER capsules	Galantamine hydrobromide	8 mg, 16 mg, 24 mg	Extended release

Galantamine is an acetylcholinesterase inhibitor. The major formulation challenge is balancing dose flexibility, gastrointestinal tolerability, release control, stability, swallowability, and cost. The strongest commercial openings are generic substitution, orally disintegrating or multiparticulate products, high-concentration liquids, excipient sourcing, and adherence-oriented extended-release systems.

What excipients are used in Razadyne tablets?

Razadyne immediate-release tablets use a conventional solid oral excipient system. The FDA labeling identifies excipients that include lactose monohydrate, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, hypromellose, talc, titanium dioxide, propylene glycol, and colorants, depending on strength and tablet presentation (Janssen Pharmaceuticals, 2010; DailyMed, 2024).

Functional role of the tablet excipients

Excipient class	Likely function in Razadyne tablets	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Low cost, broad supplier base; relevant for lactose-sensitive patients
Microcrystalline cellulose	Filler and dry binder	Supports tablet hardness and manufacturability
Crospovidone	Superdisintegrant	Controls tablet breakup and immediate release
Magnesium stearate	Lubricant	Can affect dissolution if overused
Colloidal silicon dioxide	Glidant and moisture-control aid	Supports powder flow
Hypromellose	Film coating or coating polymer	Controls appearance and protects the tablet
Talc	Anti-tacking and coating aid	Used in film-coating systems
Titanium dioxide	Opacifier and colorant	Subject to regional regulatory and customer restrictions
Propylene glycol	Film-coating plasticizer	Supports coating flexibility
Iron oxides or other colorants	Product identification	Important for strength differentiation

The immediate-release formulation is relatively accessible to generic manufacturers because it does not depend on a complex delivery technology. The principal development risks are dissolution matching, coating robustness, impurity control, tablet identification, and bioequivalence.

What excipients are used in Razadyne ER capsules?

Razadyne ER is a once-daily extended-release capsule. The formulation uses multiparticulate technology rather than a simple matrix tablet. The labeled inactive ingredients include drug-loaded beads or pellets containing materials such as sugar spheres, microcrystalline cellulose, hypromellose, ethylcellulose, polyethylene glycol, talc, magnesium stearate, gelatin, titanium dioxide, and capsule-shell colorants (Janssen Pharmaceuticals, 2010; DailyMed, 2024).

How the Razadyne ER excipient system controls release

The extended-release design generally relies on coated pellets or beads. A typical structure includes:

1. An inert or partially inert pellet core.
2. A drug-containing layer.
3. A polymeric release-controlling coating.
4. Encapsulation in a hard gelatin capsule.

Ethylcellulose is a key water-insoluble release-controlling polymer. Hypromellose can support drug-layer formation, binder performance, or film properties. Polyethylene glycol is used as a plasticizer or processing aid. Talc can reduce tack during coating. Sugar spheres and microcrystalline cellulose provide the substrate and structural support for multiparticulates.

This excipient architecture creates more development value than the immediate-release tablet because release performance depends on coating thickness, polymer permeability, pellet size distribution, drug loading, coating defects, and capsule fill uniformity.

What excipient strategy best supports a generic Razadyne product?

The optimal strategy differs by dosage form.

Immediate-release tablets

A generic tablet should prioritize:

• Direct compression or high-speed wet granulation.
• Robust tablet hardness at low tablet weight.
• Fast and reproducible disintegration.
• Dissolution matching across multiple pH conditions.
• Low lubricant sensitivity.
• Color coding that prevents medication errors.
• Lactose-free or low-lactose positioning where commercially justified.

A formulation using microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate is technically conventional. The commercial advantage would come from lower manufacturing cost, improved stability, smaller tablet size, or a differentiated excipient profile rather than from novel pharmacology.

Extended-release capsules

The ER formulation requires greater process control. Key variables include:

• Pellet diameter and size distribution.
• Drug-layer uniformity.
• Ethylcellulose coating weight gain.
• Polymer permeability.
• Plasticizer concentration.
• Residual solvent levels.
• Capsule fill weight.
• Moisture transmission.
• Alcohol-induced dose dumping risk.
• Stability after capsule opening and sprinkling, if such use is claimed.

A manufacturer can pursue a reference-matched multiparticulate product or a different extended-release technology, such as matrix pellets, coated mini-tablets, or osmotic systems. A different technology may reduce manufacturing cost but can increase bioequivalence and food-effect risk.

The preferred commercial route is usually a reference-matched pellet system. It reduces clinical and regulatory uncertainty and makes the product easier for prescribers and pharmacists to substitute.

What formulation patents protect Razadyne and galantamine products?

The original galantamine molecule and early Razadyne formulation rights are generally historic assets. Razadyne is no longer protected by the type of active U.S. exclusivity that would block routine generic development. The principal commercial barriers are formulation execution, regulatory approval, manufacturing scale, and pharmacy contracting.

Patent and exclusivity position

Issue	Commercial assessment
Active ingredient patent	Historic protection has expired or is no longer the primary barrier
Immediate-release tablet patent risk	Low relative to complex modified-release products
Extended-release formulation risk	Higher technical complexity, but not necessarily active blocking exclusivity
Method-of-use patents	Limited practical ability to prevent generic use where broad treatment indications are established
Orange Book impact	Any current listing must be verified against the FDA Orange Book at the time of filing or launch
Regulatory exclusivity	No meaningful current brand exclusivity is expected to block generic galantamine entry
Biosimilar risk	Not applicable; galantamine is a small molecule, not a biologic

The key distinction is between patent expiration and commercial difficulty. A generic developer may face substantial ER formulation work even when no enforceable patent blocks entry.

When did Razadyne lose exclusivity?

Razadyne’s original regulatory and patent exclusivity periods ended years ago. The FDA approved galantamine immediate-release products in the late 1990s and the extended-release product in the early 2000s. Generic galantamine products have been available in the United States for years, confirming that the core product is commercially off-patent.

Razadyne was previously marketed as Reminyl before the U.S. brand name changed to avoid confusion with Amaryl. Janssen Pharmaceuticals commercialized Razadyne in the United States after acquiring rights associated with galantamine development and commercialization.

Because FDA Orange Book listings and patent status can change through corrections, delistings, or litigation settlements, current diligence should rely on the live Orange Book record and applicable court dockets rather than historical brand materials (FDA, 2024a; FDA, 2024b).

What is the Orange Book status of Razadyne?

The Orange Book is relevant mainly to historical reference-listed-drug information and any remaining listed patents associated with specific dosage forms. Immediate-release galantamine tablets and oral solution have substantial generic availability. Razadyne ER has also faced generic competition, although its multiparticulate technology can make development more demanding.

A generic applicant seeking approval under an ANDA would typically evaluate:

• Whether a listed patent remains active.
• Whether a Paragraph IV certification is required.
• Whether a Paragraph III certification delays launch.
• Whether the proposed formulation falls within a listed claim.
• Whether labeling can omit protected method-of-use information.
• Whether the product meets the reference product’s release profile.

Paragraph IV challenge risk

Paragraph IV risk is most relevant when a listed patent remains in force. For a mature product such as Razadyne, the principal opportunity is not a first Paragraph IV launch but continued competition among approved generics and authorized or private-label suppliers.

For a new ER formulation, patent risk may arise from the developer’s own formulation work. A manufacturer can create new protection around pellet composition, coating architecture, capsule design, or manufacturing controls, but those claims must be drafted narrowly enough to survive validity and obviousness challenges.

Which excipient opportunities exist for galantamine products?

Lactose-free immediate-release tablets

Razadyne tablets use lactose-containing excipient systems. A lactose-free generic could target patients and institutions that prefer lactose-free products. Replacing lactose with mannitol, anhydrous dibasic calcium phosphate, or additional microcrystalline cellulose would require optimization of:

• Tablet tensile strength.
• Disintegration time.
• Dissolution.
• Moisture sensitivity.
• Powder flow.
• Tablet size.

The opportunity is commercially credible but likely modest. Most patients do not select galantamine based on excipient composition, so the product would need payer, institutional, or pharmacy-channel support.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, impaired dexterity, or difficulty swallowing capsules. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavoring systems are potential components.

The principal issues are dose uniformity, taste masking, mechanical strength, moisture protection, and the regulatory definition of an ODT. A 4 mg or 8 mg strength could be more suitable for an ODT than a 12 mg strength because of dose loading and taste intensity.

High-concentration oral solution

The marketed oral solution is 4 mg/mL. A higher-concentration product could reduce administration volume for patients receiving titration or maintenance therapy. Development would need to address:

• Solubility of galantamine hydrobromide.
• pH control.
• Preservative effectiveness.
• Chemical stability.
• Measuring-device accuracy.
• Taste masking.
• Compatibility with enteral feeding systems.

A preservative-free multidose system could have institutional value but would require a suitable container-closure and microbial-control strategy.

Improved extended-release capsules

The largest formulation opportunity is an ER capsule with improved tolerability or lower manufacturing cost. Potential approaches include:

• Lower-burst-release pellets.
• Narrower release variability across food conditions.
• Reduced alcohol sensitivity.
• Smaller capsule size.
• Capsule designs that permit sprinkling onto soft food.
• Moisture-resistant packaging.
• More efficient coating processes.

A product that reduces peak-related gastrointestinal adverse effects could support differentiation, although any clinical superiority claim would require evidence beyond routine bioequivalence.

What manufacturing and intellectual-property barriers affect Razadyne competition?

The immediate-release product has low manufacturing barriers. Standard tablet equipment and commercially available excipients are sufficient for development.

The ER capsule has higher barriers:

Barrier	Immediate-release tablet	Extended-release capsule
Powder blending	Low	Moderate
Content uniformity	Moderate	High
Dissolution control	Moderate	High
Specialized coating	Low	High
Scale-up risk	Low	High
Equipment capital	Low	Moderate to high
Excipient supplier qualification	Moderate	High
Bioequivalence risk	Moderate	High
Process patent exposure	Low	Moderate

For ER products, the key competitive asset may be the manufacturing process rather than a single excipient. Fluid-bed coating capability, in-process pellet testing, coating endpoint control, and validated dissolution methods can create a meaningful barrier to entry.

How strong is the Razadyne patent estate?

The Razadyne patent estate is commercially weak as a barrier to routine generic entry because the product has been marketed for decades and generic galantamine products are established. The formulation estate may still have historical or jurisdiction-specific value, but it is unlikely to support broad U.S. exclusivity for the original product.

A new entrant can obtain stronger protection by developing:

• A novel multiparticulate release profile.
• A defined coating composition.
• A stable high-concentration liquid.
• A taste-masked ODT.
• A device-linked oral solution.
• A manufacturing process with improved content uniformity.
• A formulation that supports capsule opening and food administration.

Patent strength will depend on claim breadth, written description, enablement, comparative dissolution data, and evidence that the formulation solves a defined technical problem.

What generic launch scenarios exist for Razadyne?

Immediate-release generic launch

This is the lowest-risk scenario. Multiple manufacturers can compete on cost, supply reliability, channel access, and tablet appearance. Margin compression is likely, particularly for the 4 mg and 8 mg strengths.

Extended-release generic launch

An ER entrant may obtain stronger pricing initially if only a limited number of approved suppliers exist. That advantage can decline quickly after additional ANDA approvals. The most important variables are approval timing, manufacturing yield, distributor access, and substitution status.

Branded-generic or authorized-generic strategy

A branded-generic supplier could package approved galantamine products under a private label, emphasizing consistent supply, institutional contracting, or specialized packaging. This strategy requires limited formulation innovation but can generate value through channel execution.

Lifecycle reformulation

A reformulated product could command higher pricing if it offers a clinically or operationally meaningful benefit. The strongest candidates are a small-volume liquid, ODT, or ER capsule with improved administration flexibility. A minor color or excipient change alone is unlikely to support premium pricing.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve technology and supply than the Razadyne brand itself.

Potential structures include:

• Contract manufacturing of galantamine tablets or capsules.
• Regional licensing of an ER multiparticulate platform.
• Excipient supplier agreements for coating polymers or functionalized fillers.
• Private-label supply to long-term-care pharmacies.
• Co-development of ODT or high-concentration liquid products.
• Acquisition of an approved ANDA with manufacturing transfer rights.
• Dual-source agreements for critical excipients.

An excipient manufacturer with a differentiated coating polymer could license a validated galantamine ER process to generic drugmakers. A contract development and manufacturing organization with fluid-bed coating capacity could offer a faster path to ER product scale-up than a tablet-focused manufacturer.

What is the FDA regulatory status of Razadyne?

Razadyne is an FDA-approved prescription product for mild-to-moderate Alzheimer’s disease. Galantamine is also approved in generic immediate-release and extended-release products. The main FDA pathway for a conventional generic is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference-listed drug (FDA, 2017).

A reformulated product that cannot qualify for an ANDA may require a 505(b)(2) application. That route could be relevant for:

• A new concentration.
• A novel dosage form.
• A materially different release system.
• A new administration method.
• A product with a different excipient composition and supporting clinical rationale.

The 505(b)(2) route may provide a more defensible commercial position but typically requires more regulatory investment than an ANDA.

Key Takeaways

• Razadyne contains galantamine hydrobromide and is available as immediate-release tablets, oral solution, and extended-release capsules.
• The immediate-release products use conventional excipients and have low technical barriers to generic manufacture.
• The ER capsule is the more valuable formulation target because multiparticulate coating creates greater process and bioequivalence complexity.
• Razadyne has no meaningful current biosimilar risk because galantamine is a small molecule.
• Historic patents and exclusivity are no longer the principal barriers to U.S. generic entry.
• The strongest commercial opportunities are ODTs, lactose-free tablets, concentrated oral solution, improved ER capsules, and private-label supply.
• Excipient innovation is more likely to support lifecycle differentiation and manufacturing efficiency than broad product exclusivity.
• A 505(b)(2) strategy may be appropriate for a materially different dosage form; conventional products generally fit the ANDA pathway.
• Revenue potential depends on formulation differentiation, pharmacy substitution, payer access, and manufacturing cost rather than on the original Razadyne brand estate.

FAQs About Razadyne Excipients and Commercial Strategy

Can lactose-free galantamine tablets be developed?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable diluent. The developer must match tablet performance, dissolution, stability, and bioequivalence.

Is a galantamine orally disintegrating tablet commercially attractive?

It can address swallowing difficulties and administration challenges in Alzheimer’s patients. Commercial value depends on taste masking, strength selection, reimbursement, and whether the product achieves meaningful pharmacy or institutional adoption.

Does Razadyne ER require a specialized coating process?

Yes. The extended-release product relies on multiparticulate technology that requires controlled drug layering and polymer coating. Fluid-bed processing and tight pellet-size control are typically important for consistent release.

Can a new galantamine liquid obtain meaningful exclusivity?

A new liquid may obtain formulation or method patents if it has a technically distinctive concentration, preservative system, delivery device, or stability profile. Patent protection would depend on the specific formulation claims and their validity.

Are biosimilars a competitive threat to Razadyne?

No. Galantamine is a chemically synthesized small molecule. Competition comes from generic tablets, oral solutions, extended-release capsules, and potential lifecycle reformulations rather than biosimilars.

References

1. DailyMed. (2024). Galantamine hydrobromide: Prescribing information and inactive ingredients. U.S. National Library of Medicine.

2. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly variable drugs. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.

5. Janssen Pharmaceuticals, Inc. (2010). Razadyne and Razadyne ER prescribing information. Titusville, NJ: Janssen Pharmaceuticals.